Drugs / HLX60
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05483530 | Dec 2022 → Dec 2024 | — | Shanghai Henlius Biotech | Unknown | No outcome recorded |
| Phase 1 | NCT05606380 | Dec 2022 → Aug 2024 | lymphoma | Shanghai Henlius Biotech | Unknown | No outcome recorded |
News releases announcing trial results or a regulatory action · 2
| Date | Issuer | Release |
|---|---|---|
| 2022-10-17 | Shanghai Henlius Biotech | Regulatory The IND Application of Henlius’ Novel Anti-GARP mAb HLX60 Approved by NMPA henlius.com ↗
Shanghai, China, Oct 17th, 2022 - Shanghai Henlius Biotech, Inc. (2696.HK) announced that the investigational new drug (IND) application for clinical trial of HLX60 (recombinant anti-GARP humanised monoclonal antibody injection), independently developed by the company, was approved by the National Medical Products Administration (NMPA) for the treatment of solid tumours and lymphomas. |
| 2022-08-26 | Shanghai Henlius Biotech | Regulatory Henlius Novel Anti-GARP and Anti-PD-1 Dual mAb Therapy Received Clinical Trial Approval in Australia henlius.com ↗
Clinical Trial Notification (CTN) has been acknowledged by the Therapeutic Goods Administration (TGA), Australia. |
All press releases naming this drug 3 releases
| Date | Issuer | Release |
|---|---|---|
| 2022-12-02 | Shanghai Henlius Biotech | First Subject Dosed for Phase 1 Clinical Trial of Henlius’ Novel Anti-GARP mAb HLX60 henlius.com ↗ |
| 2022-10-17 | Shanghai Henlius Biotech | The IND Application of Henlius’ Novel Anti-GARP mAb HLX60 Approved by NMPA henlius.com ↗ |
| 2022-08-26 | Shanghai Henlius Biotech | Henlius Novel Anti-GARP and Anti-PD-1 Dual mAb Therapy Received Clinical Trial Approval in Australia henlius.com ↗ |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | HLX60 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05483530 ↗ |
| Modality | Monoclonal antibody | “HLX60 (Anti-GARP Monoclonal Antibody)” NCT05483530 ↗ |
| Route | Intravenous | “intravenous infusion” NCT05606380 ↗ |